BioPharma

FDA approves Novartis drug to treat pain crises in sickle cell disease

With the approval, Novartis will be able to sell its drug to sickle cell disease patients to reduce the frequency of sudden pain crises in adult and pediatric patients aged 16 years and older suffering from the genetic disorder.

Red seal and imprint "FDA APPROVED" on white surface. FDA - Food and Drug Administration is a federal agency of the United States Department of Health and Human Services.

 

Novartis announced late Friday that the Food and Drug Administration has approved Adakveo — formerly called SEG101 — to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult and pediatric patients aged 16 years and older with sickle cell disease.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

The drug (crizanlizumab) happens to be the first FDA-blessed drug in sickle cell disease that binds to the protein P-selectin that works in cell adhesion – the process by which cells interact with specific molecules on the cell surface and attach to adjacent cells – and plays a key role in multicellular interactions that can lead to pain crises.

The Swiss company announced that the drug would be available in the coming weeks.

The FDA’s decision to approve Adakveo is based on the results of the year-long randomized, placebo-controlled SUSTAIN trial, which showed that Adakveo significantly lowered the median annual rate of VOCs to 1.63 vs 2.98 compared to placebo (P=.010). That equals a 45% reduction.

Perhaps more notably, these reductions in the frequency of VOCs were seen among patients regardless of sickle cell disease genotype and/or hydroxyurea use. Hydroxyurea is used to treat chronic myeloid leukemia, ovarian cancer, and certain types of skin cancer.

“We know this drug can decrease the frequency of sickle cell pain crises in a significant and clinically meaningful way,” said Dr. Kenneth Ataga,  director, Center for Sickle Cell Disease, University of Tennessee Health Science Center at Memphis, and principal investigator of the SUSTAIN trial, in a news release. “The approval of crizanlizumab is an important advancement for people living with this very difficult condition.”

Novartis also noted other results from the randomized trial:

  • A decrease in the median annual rate of days hospitalized to 4 vs 6.87 days when compared with placebo (a 42% reduction)

  • Thirty-six percent of patients treated with Adakveo did not experience a VOC, compared to 17% of placebo-treated patients

  • The median time to first VOC was 4.1 for Adakveo vs 1.4 months for placebo

The most common negative reaction that patients experienced were nausea (18%), arthralgia (18%), back pain (15%) and pyrexia (fever) (11%).

The approval could especially be a boon for patients who suffer pain crises because the condition is often undertreated out of fear that it might lead patients to be addicted to narcotics. Such pain crises are one of the top reasons for sickle cell disease patients ending up in the emergency room. The genetic disease overwhelmingly affects people of African descent in the U.S. with the total number of patients numbering around 100,000 according to an estimate from the American Society of Hematology.

“The approval of Adakveo marks a new era in the treatment of sickle cell disease, a genetic condition that places an extraordinary burden of unpredictable pain crises on patients and their families,” said Susanne Schaffert, president, Novartis Oncology, in a news release. “The stories we have heard from patients about their sickle cell pain crises are devastating. We are pleased to help reimagine medicine together with the sickle cell community and offer new hope for fewer VOCs.”

Photo: Waldemarus, Getty Images